Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway

Oncogene

Volumn 26, Issue 51, 2007, Pages 7213-7221

  Mak, H H L ^a,b   Peschard, P ^a,b   Lin, T ^b   Naujokas, M A ^b   Zuo, D ^b   Park, M ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cbl; Endocytosis; RTK; Signal transduction; Transforming gene; Ubiquitin

Indexed keywords

CBL PROTEIN; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BINDING SITE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DOWN REGULATION; EMBRYO; ENDOSOME; GENE ACTIVATION; GENE ACTIVITY; GENE LOCATION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; UBIQUITINATION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; COS CELLS; DNA PRIMERS; ENDOCYTOSIS; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; ONCOGENE PROTEIN TPR-MET; ONCOGENES; SUBCELLULAR FRACTIONS; UBIQUITIN;

EID: 36049051915     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210522     Document Type: Article

References (28)

1. Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, Urbe S et al. (2005). Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25: 9632-9645.
2. Bache KG, Slagsvold T, Stenmark H. (2004). Defective downregulation of receptor tyrosine kinases in cancer. EMBO J 23: 2707-2712.
3. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411: 355-365.
4. Carter S, Urbe S, Clague MJ. (2004). The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 279: 52835-52839.
5. Grovdal LM, Stang E, Sorkin A, Madshus IH. (2004). Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300: 388-395.
6. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I. (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5: 461-466.
7. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. (2006). Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 21: 737-748.
8. Katzmann DJ, Odorizzi G, Emr SD. (2002). Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 3: 893-905.
9. Lamorte L, Park M. (2001). The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am 10: 271-288, viii.
10. Lee PS, Wang Y, Dominguez MG, Yeung YG, Murphy MA, Bowtell DD et al. (1999). The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J 18: 3616-3628.
11. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY et al. (1998). c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12: 3663-3674.
12. Miyake S, Lupher Jr ML, Druker B, Band H. (1998). The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci USA 95: 7927-7932.
13. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J et al. (2003). Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278: 21323-21326.
14. Naslavsky N, Weigert R, Donaldson JG. (2003). Convergence of non-clathrin- and clathrin-derived endosomes involves Arf6 inactivation and changes in phosphoinositides. Mol Biol Cell 14: 417-431.
15. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG et al. (1986). Mechanism of met oncogene activation. Cell 45: 895-904.
16. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY et al. (2001). Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8: 995-1004.
17. Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. (2004). A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem 279: 29565-29571.
18. Peschard P, Park M. (2003). Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3: 519-523.
19. Rodrigues GA, Naujokas MA, Park M. (1991). Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 11: 2962-2970.
20. Rodrigues GA, Park M. (1993). Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol 13: 6711-6722.
21. Rodrigues GA, Park M. (1994). Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev 4: 15-24.
22. Shtiegman K, Yarden Y. (2003). The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol 13: 29-40.
23. Thien CB, Langdon WY. (2005). c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem J 391: 153-166.
24. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. (2000). Recognition of the polyubiquitin proteolytic signal. EMBO J 19: 94-102.
25. Urbe S, Sachse M, Row PE, Preisinger C, Barr FA, Strous G et al. (2003). The UIM domain of Hrs couples receptor sorting to vesicle formation. J Cell Sci 116: 4169-4179.
26. Vigna E, Gramaglia D, Longati P, Bardelli A, Comoglio PM. (1999). Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPRMET. Oncogene 18: 4275-4281.
27. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A et al. (2002). A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21: 303-313.
28. Waterman H, Levkowitz G, Alroy I, Yarden Y. (1999). The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 274: 22151-22154.